Abstract:center dot MMF has been proposed as a treatment of steroid-dependent nephrotic syndrome and in the recent years, several studies have suggested its positive effect in preventing relapses.WHAT THIS PAPER ADDScenter dot The population pharmacokinetics of MPA was first evaluated in children with idiopathic nephrotic syndrome and data fitted well with a two-compartment model with first-order absorption and lag time.center dot Body weight and serum albumin had a significant impact on oral clearance.center dot A three-point (T-0, T-1 and T-4h) Bayesian estimator of AUC(0-12) was developed.AIMSTo develop a population pharmacokinetic model for mycophenolic acid (MPA) in children with idiopathic nephrotic syndrome (INS) treated with mycophenolate mofetil (MMF), identify covariates that explain variability and determine the Bayesian estimator of the area under the concentration-time curve over 12 h (AUC(0-12)).METHODSThe pharmacokinetic model of MMF was described from 23 patients aged 7.4 +/- 3.9 years (range 2.9-14.9) using nonlinear mixed-effects modelling (NONMEM) software. A two-compartment model with lag-time and first-order absorption and elimination was developed. The final model was validated using visual predictive check. Bayesian estimator was validated using circular permutation method.RESULTSThe population pharmacokinetic parameters were apparent oral clearance 9.7 l h-1, apparent central volume of distribution 22.3 l, apparent peripheral volume of distribution 250 l, inter-compartment clearance 18.8 l h-1, absorption rate constant 5.16 h-1, lag time 0.215 h. The covariate analysis identified body weight and serum albumin as individual factors influencing the apparent oral clearance. Accurate Bayesian estimation of AUC(0-12) was obtained using the combination of three MPA concentrations measured just before (T-0), 1 and 4 h (T-1 and T-4) after drug intake with a small error of 0.298 mu g h-1 ml-1 between estimated and reference AUC(0-12).CONCLUSIONSThe population pharmacokinetic model of MPA was developed in children with INS. A three-point (T-0, T-1 and T(4)h) Bayesian estimator of AUC(0-12) was developed and might be used to investigate the relation between MPA pharmacokinetic and pharmacodynamics in children with INS and determine if there is any indication to monitor MPA exposure in order to improve patient outcome based on individual AUC-controlled MMF dosing.

Identification of Biomarkers That Predict Renal Flare in Childhood-Onset Lupus Nephritis with Mycophenolate Acid.

Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study

Early-stage predictors for treatment responses in patients with active lupus nephritis.

Pharmacokinetics of Mycophenolic Acid in Chinese Kidney Transplant Patients

Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis

Exposure Levels of Mycophenolic Acid Are Associated with Comorbidities in Children with Systemic Lupus Erythematosus.

Pk/Pd Study Of Mycophenolate Mofetil In Children With Systemic Lupus Erythematosus To Inform Model-Based Precision Dosing

Limited Sampling Strategy for Mycophenolic Acid in Chinese Kidney Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus During the Early Posttransplantation Phase

Therapeutic drug monitoring of mycophenolic acid and clinical outcomes of lupus nephritis: a systematic review and meta-analysis

Machine Learning For Prediction And Risk Stratification Of Lupus Nephritis Renal Flare

Population Pharmacokinetics and Bayesian Estimator of Mycophenolic Acid in Children with Idiopathic Nephrotic Syndrome

Population pharmacokinetic and dose optimization of mycophenolic acid in children with anti-neutrophilic cytoplasmic antibody-associated nephritis

Increased urinary levels of monocyte chemotactic protein 1 and macrophage colony-stimulating factor are predictors of lupus nephritis flare

Short-Term Intensified Dosage Regimen of Mycophenolic Acid is Associated with Less Acute Rejection in Kidney Transplantation from Donation after Circulatory Death.

Cystatin C and myeloperoxidase based mycophenolic acid dosage optimization in pediatric anti-neutrophilic cytoplasmic antibody-associated nephritis

The Application of Podocyte Antigen PLA2R and Anti-Pla2r Antibody in the Diagnosis and Treatment of Membranous Nephropathy

Estimation Of Optimal Minimum Dosage Of Mycophenolate Mofetil In Children With Various Glomerular Diseases

Validated LC-MS/MS Method for Quantitation of Total and Free Mycophenolic Acid Concentration and Its Application to a Pharmacokinetic Study in Pediatric Renal Transplant Recipients.

Relationship Between Blood Concentration of Mycophenolate Mofetil and Adverse Drug Reaction(adr) in Lupusnephritis

Predicting decline of kidney function in lupus nephritis using urine biomarkers

Urine Biomarkers to Predict Response to Lupus Nephritis Therapy in Children and Young Adults